文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

成纤维细胞生长因子21通过抑制NLRP3/caspase-1/GSDMD焦亡通路减轻呼吸机诱导肺损伤

Fibroblast growth factor 21 attenuates ventilator-induced lung injury by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway.
PubMed 文献 · Crit Care · 2023-05-22
一句话结论临床与小鼠数据提示VILI时内源性FGF21信号被激活,补充重组FGF21可减轻VILI,机制为抑制NLRP3/caspase-1/GSDMD焦亡通路。

本研究在全身麻醉机械通气患者和小鼠VILI模型中检测血清FGF21,并比较FGF21基因敲除(KO)与野生型(WT)小鼠的肺损伤;同时在体内和体外给予重组FGF21以评估治疗作用。结果显示VILI患者和小鼠血清FGF21水平显著高于无VILI者,且麻醉患者血清FGF21升高幅度与通气时长正相关;FGF21-KO小鼠较WT小鼠VILI加重,而给予FGF21可减轻小鼠和细胞模型的VILI。机制上FGF21降低caspase-1活性、抑制Nlrp3、Asc、Il-1β、Il-18、Hmgb1和Nf-κb的mRNA水平,并降低NLRP3、ASC、IL-1β、IL-18、HMGB1及GSDMD剪切体的蛋白水平。作者认为增强内源性FGF21或给予重组FGF21可能成为麻醉或重症监护期间VILI的治疗策略。

要点

  • VILI患者和小鼠血清FGF21水平显著高于无VILI者,麻醉患者血清FGF21升高幅度与通气时长正相关。
  • FGF21基因敲除小鼠较野生型小鼠VILI加重,提示内源性FGF21对VILI具有保护作用。
  • 给予重组FGF21可在小鼠和细胞模型中减轻VILI。
  • FGF21降低caspase-1活性,抑制Nlrp3、Asc、Il-1β、Il-18、Hmgb1和Nf-κb的mRNA水平,并降低NLRP3、ASC、IL-1β、IL-18、HMGB1及GSDMD剪切体的蛋白水平。
  • 作者认为增强内源性FGF21或给予重组FGF21可能成为麻醉或重症监护期间VILI的潜在治疗策略。

适用人群与场景

  • 接受全身麻醉机械通气的患者
  • 小鼠VILI模型

研究设计与关键结果

  • 研究检测了全身麻醉机械通气患者和小鼠VILI模型的血清FGF21浓度,比较FGF21基因敲除(KO)小鼠与野生型(WT)小鼠的肺损伤,并在体内和体外给予重组FGF21以评估治疗作用。
  • VILI患者和小鼠血清FGF21水平显著高于无VILI者;麻醉患者血清FGF21升高幅度与通气时长正相关。
  • FGF21-KO小鼠较WT小鼠VILI加重;给予FGF21可减轻小鼠和细胞模型的VILI。
  • FGF21降低caspase-1活性,抑制Nlrp3、Asc、Il-1β、Il-18、Hmgb1和Nf-κb的mRNA水平,并降低NLRP3、ASC、IL-1β、IL-18、HMGB1及GSDMD剪切体的蛋白水平。

证据类型、等级与局限

  • 证据类型:基础与转化研究(患者血清检测、小鼠VILI模型、细胞模型)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为增强内源性FGF21或给予重组FGF21可能成为麻醉或重症监护期间VILI的潜在治疗策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ventilator-induced lung injury (VILI) is caused by overdistension of the alveoli by the repetitive recruitment and derecruitment of alveolar units. This study aims to investigate the potential role and mechanism of fibroblast growth factor 21 (FGF21), a metabolic regulator secreted by the liver, in VILI development.

METHODS: Serum FGF21 concentrations were determined in patients undergoing mechanical ventilation during general anesthesia and in a mouse VILI model. Lung injury was compared between FGF21-knockout (KO) mice and wild-type (WT) mice. Recombinant FGF21 was administrated in vivo and in vitro to determine its therapeutic effect.

RESULTS: Serum FGF21 levels in patients and mice with VILI were significantly higher than in those without VILI. Additionally, the increment of serum FGF21 in anesthesia patients was positively correlated with the duration of ventilation. VILI was aggravated in FGF21-KO mice compared with WT mice. Conversely, the administration of FGF21 alleviated VILI in both mouse and cell models. FGF21 reduced Caspase-1 activity, suppressed the mRNA levels of Nlrp3, Asc, Il-1β, Il-18, Hmgb1 and Nf-κb, and decreased the protein levels of NLRP3, ASC, IL-1β, IL-18, HMGB1 and the cleaved form of GSDMD.

CONCLUSIONS: Our findings reveal that endogenous FGF21 signaling is triggered in response to VILI, which protects against VILI by inhibiting the NLRP3/Caspase-1/GSDMD pyroptosis pathway. These results suggest that boosting endogenous FGF21 or the administration of recombinant FGF21 could be promising therapeutic strategies for the treatment of VILI during anesthesia or critical care.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Ding P, Yang R, Li C, et al. Fibroblast growth factor 21 attenuates ventilator-induced lung injury by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway. Crit Care. 2023. PMID: 37218012. doi:10.1186/s13054-023-04488-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。